Pitfalls in patenting academic CAR-T cells therapy

References

• Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017 Feb 21;10(1):53. doi: 10.1186/s13045-017-0423-1
   PubMedGoogle Scholar
• Tomuleasa C, Fuji S, Berce C, et al. Chimeric antigen receptor T-Cells for the treatment of B-Cell acute lymphoblastic leukemia. Front Immunol. 2018;9:239.
   PubMed Web of Science ®Google Scholar
• Shang S, Zhao Y, Qian K, et al. The role of neoantigens in tumor immunotherapy. Biomed Pharmacother Biomed Pharmacother. 2022 Jul;151:113118.
   PubMed Web of Science ®Google Scholar
• Gupta SL, Basu S, Soni V, et al. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep. 2022 Oct;49(10):9903–9913. doi: 10.1007/s11033-022-07525-8
   Web of Science ®Google Scholar
• Aggarwal S, Chandra A. Patentability challenges associated with emerging pharmaceutical technologies. Pharm Pat Anal. 2021 Jul;10(4):195–207.
   PubMed Web of Science ®Google Scholar
• Moretti A, Ponzo M, Nicolette CA, et al. The past, present, and future of Non-Viral CAR T Cells. Front Immunol. 2022;13:867013.
   PubMed Web of Science ®Google Scholar
• Numbenjapon T, Serrano LM, Chang WC, et al. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells. Exp Hematol. 2007 Jul;35(7):1083–1090.
   PubMed Web of Science ®Google Scholar
• Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet Lond Engl. 2022 Jun 18;399(10343):2294–2308.
   Google Scholar
• Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022 Jun;28(6):1189–1198.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen X, Han W, et al. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today Barc Spain 1998. 2017 Nov;53(11):597–608.
   Google Scholar
• FDA approves second CAR T-cell therapy. Cancer Discov. 2018 Jan;8(1):5–6. doi: 10.1158/2159-8290.CD-NB2017-155
   PubMed Web of Science ®Google Scholar
• Beyar-Katz O, Gill S. Advances in chimeric antigen receptor T cells. Curr Opin Hematol. 2020 Nov;27(6):368–377.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 Feb 25;384(8):705–716.
   PubMed Web of Science ®Google Scholar
• Golumba-Nagy V, Kuehle J, Abken H. Genetic modification of t cells with chimeric antigen receptors: a laboratory manual. Hum Gene Ther Methods. 2017 Dec;28(6):302–309.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017 May 24;545(7655):423–431.
   PubMed Web of Science ®Google Scholar
• Ochi T, Fujiwara H, Okamoto S, et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood. 2011 Aug 11;118(6):1495–1503.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013 Apr;3(4):388–398.
   PubMed Web of Science ®Google Scholar
• Bunse M, Höpken UE. Generation of redirected engineered human chimeric antigen receptor (CAR) T cells. Methods Mol Biol Clifton NJ. 2022;2521:67–83.
   PubMedGoogle Scholar
• Zhang X, Zhu L, Zhang H, et al. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022 Jun 10;13:927153.
   PubMed Web of Science ®Google Scholar
• Duan D, Wang K, Wei C, et al. The BCMA-Targeted fourth-generation car-t cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma. Front Immunol. 2021;12:609421.
   PubMed Web of Science ®Google Scholar
• Charrot S, Hallam S. CAR-T cells: future perspectives. Hemasphere. 2019 Mar 19;3(2):e188.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019 Mar;34:45–55.
   PubMed Web of Science ®Google Scholar
• Abinader L, Contreras J The patentability of genetic therapies: cAR-T and medical treatment exclusions around the world. Utah Law Fac Scholarsh [Internet]. [cited 2023 Mar 26]. 2019 Jun 1; Available from: https://dc.law.utah.edu/scholarship/160
   Google Scholar
• Jürgens B, Clarke NS. Evolution of CAR T-cell immunotherapy in terms of patenting activity. Nat Biotechnol. 2019 Apr;37(4):370–375.
   PubMed Web of Science ®Google Scholar
• Grosser R, Cherkassky L, Chintala N, et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019 Nov 11;36(5):471–482.
   PubMed Web of Science ®Google Scholar
• Hosseinkhani N, Derakhshani A, Kooshkaki O, et al. Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies? Int J Mol Sci. 2020 Nov 5;21(21):8305.
   PubMed Web of Science ®Google Scholar
• Liu DC-T. “The living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol OncolJ Hematol Oncol. 2019 Nov 8;12(1):113.
   PubMed Web of Science ®Google Scholar
• Guidelines for Preparing Patent Landscape Reports [Internet]. [cited 2023 Mar 26]. Available from: https://www.wipo.int/publications/en/details.jsp?id=3938
   Google Scholar
• Patent issues in CAR-T technology [Internet]. [cited 2023 Mar 26]. Available from: https://www.iam-media.com/global-guide/global-life-sciences/2020/article/patent-issues-in-car-t-technology
   Google Scholar
• US appeals court rules in favour of Kite in Gilead-BMS patent dispute [Internet]. Pharmaceutical Technology. 2021 [cited 2023 Mar 25]. Available from: https://www.pharmaceutical-technology.com/analysis/us-appeals-court-kite-gilead-bms-patent/
   Google Scholar
• Methods of medical treatment patentable in Australia; infringement by cross-label use fact-dependent - knowledge - Clayton Utz [Internet]. [cited 2023 Mar 25]. Available from: https://www.claytonutz.com/knowledge/2013/december/methods-of-medical-treatment-patentable-in-australia-infringement-by-cross-label-use-fact-dependent
   Google Scholar
• Rai AK. Fostering cumulative innovation in the biopharmaceutical industry: the role of patents and antitrust. Berkeley Technol Law J. 2001;16(2):813–853.
   Google Scholar
• European Patent Office (EPO), Japan Patent Office (JPO) and United States Patent and Trademark Office (USPTO). European patent office, Japan Patent Office and United States patent and trademark office, trilateral project B3b: mutual understanding in search and examination: report on comparative study on biotechnology patent practices (2001). Annex. 2001;2:43.
   Google Scholar
• Dardevet L, Rani D, Aziz TAE, et al. Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion. Toxins (Basel). 2015 Mar 27;7(4):1079–1101.
   PubMed Web of Science ®Google Scholar
• Isolated genetic material confirmed as patentable [Internet]. [cited 2023 Mar 26]. Available from: https://www.allens.com.au/insights-news/insights/2014/09/isolated-genetic-material-confirmed-as-patentable/
   Google Scholar
• Varkey B. Principles of clinical ethics and their application to practice. Med Princ Pract. 2021;30(1):17–28.
   PubMed Web of Science ®Google Scholar
• Office EP The European Patent Convention [Internet]. [cited 2023 Mar 26]. Available from: https://www.epo.org/law-practice/legal-texts/epc.html
   Google Scholar
• United States court of appeals for the federal circuit - JUNO THERAPEUTICS, INC., SLOAN KETTERING INSTITUTE for CANCER RESEARCH, Plaintiffs-Appellees v. KITE PHARMA, INC., Defendant-Appellant [Internet]. [cited 2023 Mar 26]. 2021. Available from: http://cafc.uscourts.gov/sites/default/files/opinions-orders/20-1758.OPINION.8-26-2021_1825257.pdf
   Google Scholar
• Freedom to Operate (FTO) [Internet]. Practical Law. [cited 2023 Mar 26]. Available from: http://uk.practicallaw.thomsonreuters.com/2-511-4689?transitionType=Default&contextData=sc.Default&firstPage=true
   Google Scholar
• Gillet R, Bouquin N. DISRUPTIVE CAR-T THERAPY is DRIVING a NEW WAVE of PATENTING CHALLENGES. 2020;2:44–51. Available from: https://www.mabdesign.fr/wp-content/uploads/2020/11/Immunowatch-Edition-2-CAR-T-cell-1.pdf
   Google Scholar
• Art Search - IPTeL P, IISc [Internet]. [cited 2023 Mar 26]. Available from: https://iptel.iisc.ac.in/prior-art-search/
   Google Scholar